An entire exon 3 germ-line rearrangement in the BRCA2 gene: Pathogenic relevance of exon 3 deletion in breast cancer predisposition

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Muller, Danièle ^a   Rouleau, Etienne ^b   Schultz, Inès ^a   Caputo, Sandrine ^b   Lefol, Cédrick ^b   Bièche, Ivan ^b   Caron, Olivier ^c   Noguès, Catherine ^b   Limacher, Jean M ^c   Demange, Liliane ^b   Lidereau, Rosette ^b   Fricker, Jean P ^a   Abecassis, Joseph ^a  

^a CENTRE PAUL STRAUSS   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA; PRIMER DNA;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SUSCEPTIBILITY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA POLYMORPHISM; EXON; EXON 3; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; OVARY TUMOR; PEDIGREE; POINT MUTATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BREAST NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA PRIMERS; DNA, NEOPLASM; EXONS; FEMALE; GENE REARRANGEMENT; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; PEDIGREE; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 80053173229     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-121     Document Type: Article

References (41)

1. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004, 95(11):866-871. 10.1111/j.1349-7006.2004.tb02195.x, 15546503.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333. 10.1200/JCO.2006.09.1066, 2267287, 17416853.
3. Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, et al. The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet 2006, 43(9):e49. 10.1136/jmg.2005.040212, 16950820.
4. Zou JP, Hirose Y, Siddique H, Rao VN, Reddy ES. Structure and expression of variant BRCA2a lacking the transactivation domain. Oncol Rep 1999, 6(2):437-440.
5. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Nogues C, Pierret J, Puy-Pernias S, et al. Identification and management of hereditary breast-ovarian cancers (2004 update). Pathol Biol (Paris) 2006, 54(4):230-250.
6. Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 2002, 20(3):218-226. 10.1002/humu.10108, 12203994.
7. Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M, Mazoyer S, Coulet F, Hardouin A, Chompret A, et al. Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 2004, 64(22):8143-8147. 10.1158/0008-5472.CAN-04-2467, 15548676.
8. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003, 63(7):1449-1453.
9. Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, Nogues C, Bieche I, Lidereau R. High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1. Clin Genet 2007, 72(3):199-207. 10.1111/j.1399-0004.2007.00849.x, 17718857.
10. Diez O, Gutierrez-Enriquez S, Ramon Y, Cajal T, Alonso C, Balmana J, Llort G. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 2007, 25(31):5035-5036; author reply 5036-5038. 10.1200/JCO.2007.13.4346, 17971607.
11. Machado P, Vaz F. Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation. Breast Cancer Res Treat 2009, 116(3):617-618. 10.1007/s10549-008-0124-0, 18633700.
12. Peixoto A, Santos C, Rocha P, Pinto P, Bizarro S, Teixeira MR. Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. Breast Cancer Res Treat 2009, 117(1):215-217. 10.1007/s10549-008-0214-z, 18853249.
13. Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren A, Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 1998, 58(7):1372-1375.
14. Machado PM, Brandao RD, Cavaco BM, Eugenio J, Bento S, Nave M, Rodrigues P, Fernandes A, Vaz F. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 2007, 25(15):2027-2034. 10.1200/JCO.2006.06.9443, 17513806.
15. Teugels E, De Brakeleer S, Goelen G, Lissens W, Sermijn E, De Greve J. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 2005, 26(3):284.
16. Peixoto A, Santos C, Rocha P, Pinheiro M, Principe S, Pereira D, Rodrigues H, Castro F, Abreu J, Gusmao L, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat 2009, 114(1):31-38. 10.1007/s10549-008-9978-4, 18363094.
17. Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmao L, Amorim A, van der Hout A, Gerdes AM, et al. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat 2011, 127(3):671-679. 10.1007/s10549-010-1036-3, 20652400.
18. Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto O, Zavagno G, Chieco-Bianchi L, D'Andrea E, et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 2005, 42(10):e64. 10.1136/jmg.2005.032789, 1735936, 16199546.
19. Bieche I, Lidereau R. Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. Cancer Res 1999, 59(11):2546-2550.
20. Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, Kirchhoff T, Wong N, Armel S, Chong G, Narod SA, et al. Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A > G (p.I2285V) variant. Hum Mutat 2009, 30(11):1543-1550. 10.1002/humu.21101, 19795481.
21. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008, 45(7):438-446. 10.1136/jmg.2007.056895, 18424508.
22. Claes K, Vandesompele J, Poppe B, Dahan K, Coene I, De Paepe A, Messiaen L. Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene. Oncogene 2002, 21(26):4171-4175. 10.1038/sj.onc.1205520, 12037674.
23. Santarosa M, Viel A, Boiocchi M. Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2. Genes Chromosomes Cancer 1999, 26(4):381-382. 10.1002/(SICI)1098-2264(199912)26:4<381::AID-GCC14>3.0.CO;2-N, 10534775.
24. UMD french data base. , http://www.umd.be/BRCA2/
25. Koul A, Nilbert M, Borg A. A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer 1999, 24(3):207-212. 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3, 10451700.
26. Breast cancer international core database (BIC). , http://research.nhgri.nih.gov/bic/
27. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 2001, 27(1):55-58. 10.1038/83762, 11137998.
28. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 2002, 11(23):2805-2814. 10.1093/hmg/11.23.2805, 12393792.
29. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. Nature 1997, 386(6627):772-773. 10.1038/386772a0, 9126734.
30. Milner J, Fuks F, Hughes-Davies L, Kouzarides T. The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase. Oncogene 2000, 19(38):4441-4445. 10.1038/sj.onc.1203793, 10980621.
31. May GH, Harris F, Gillespie D, Black DM. The BRCA2 transactivation domain does not interact with JNK. Genes Chromosomes Cancer 1999, 25(4):407-409. 10.1002/(SICI)1098-2264(199908)25:4<407::AID-GCC16>3.0.CO;2-I, 10398438.
32. Lin HR, Ting NS, Qin J, Lee WH. M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J Biol Chem 2003, 278(38):35979-35987. 10.1074/jbc.M210659200, 12815053.
33. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003, 115(5):523-535. 10.1016/S0092-8674(03)00930-9, 14651845.
34. Yao J, Polyak K. EMSY links breast cancer gene 2 to the 'Royal Family'. Breast Cancer Res 2004, 6(5):201-203. 10.1186/bcr916, 549177, 15318925.
35. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004, 10(17):5785-5791. 10.1158/1078-0432.CCR-03-0410, 15355907.
36. van Hattem WA, Carvalho R, Li A, Offerhaus GJ, Goggins M. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol 2008, 1(4):343-351. 2480540, 18787609.
37. King MC. A novel BRCA2-binding protein and breast and ovarian tumorigenesis. N Engl J Med 2004, 350(12):1252-1253. 10.1056/NEJMcibr033528, 15028830.
38. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006, 22(6):719-729. 10.1016/j.molcel.2006.05.022, 16793542.
39. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009, 7(7):1110-1118. 10.1158/1541-7786.MCR-09-0123, 19584259.
40. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005, 65(2):417-426.
41. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004, 75(4):535-544. 10.1086/424388, 1182042, 15290653.